Michael Pearson had an audacious plan when he took the helm at Valeant Pharmaceuticals International Inc. in 2008.

Departing from industry norms, he called for Valeant to slash research and development and pursue a campaign of takeovers. The acquisitions, he warned his directors, would be conducted at such a rapid pace that he insisted they be available at all hours to approve deals.

“We...